Added to YB: 2025-12-30
Pitch date: 2025-12-29
DCTH [bullish]
Delcath Systems, Inc.
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe.
Market Cap
$363.7M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
44.63
P/E
298.50
EV/Sales
3.46
Sector
Health Care Equipment and Supplies
Category
growth
Show full summary:
The portfolio I am taking into 2026 - Delcath Systems, Inc.
DCTH: US biotech w/ HEPZATO drug-device combo for metastatic uveal melanoma. Recent promising study results w/ immunotherapy could expand TAM from $500M to several billion USD. Trading 30x PE, 3x EV/Sales for 2026; 12x PE, 2.4x EV/Sales for 2027. CEO insider buying + buyback program.
Read full article (1 min)